Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Ongericimab Humanized Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA5-59617
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG4SP
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Lyophilized
浓度
1 mg/mL
纯化类型
Protein A
保存液
25mM histidine, pH 6.2, with 8% sucrose, 0.01% Tween 80
内含物
no preservative
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Dry ice (international)
RRID
产品详细信息
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
靶标信息
Ongericimab, also known as a recombinant humanized anti-PCSK9 monoclonal antibody, is primarily used to treat hypercholesterolemia by reducing low-density lipoprotein cholesterol (LDL-C) levels. The PCSK9 gene, located on chromosome 1p32.3, spans 22 kilobases and consists of 12 exons and 11 introns. It encodes a 692 amino acid glycoprotein involved in lipid metabolism, comprising a signal peptide (amino acids 1-30), a prosegment or inhibitory prodomain (amino acids 31-152), a subtilisin-like catalytic domain (amino acids 153-452), and a cysteine-histidine-rich C-terminal domain. PCSK9 plays a pivotal role in cholesterol homeostasis by promoting the degradation of low-density lipoprotein receptors (LDLR) in the liver, thereby increasing plasma LDL levels. Mutations in PCSK9 can lead to disorders such as familial hypercholesterolemia. In addition to its well-established role in cardiovascular diseases, emerging research indicates that PCSK9 variants may influence cancer outcomes and that PCSK9 inhibition can enhance the efficacy of immune checkpoint therapies.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
